Focused Ultrasound Platform for Investigating Therapeutic Neuromodulation Across the Human Hippocampus |
| |
| Affiliation: | 2. Department of Physics, Simmons College, Boston, Massachusetts, USA;3. Center for Neurorestoration and Neurotechnology, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA;4. Butler Hospital, Providence, Rhode Island, USA;5. Department of Psychiatry, Brigham and Women''s Hospital, Harvard Medical School, Boston, Massachusetts, USA;1. Department of Statistics, Feng Chia University, Taichung, Taiwan, ROCn;2. Department of Computer Science and Information Management, Hungkuang University, No. 1018, Sec. 6, Taiwan Boulevard, Shalu District, Taichung 43302, Taiwan, ROCn;2. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA;3. Department of Psychiatry, Brigham & Women''s Hospital, Harvard Medical School, Boston, Massachusetts, USA;4. Butler Hospital, Providence, Rhode Island, USA;5. Center for Neurorestoration and Neurotechnology, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA |
| |
| Abstract: | Pulsed low-intensity focused ultrasound (PLIFUS) has shown promise in inducing neuromodulation in several animal and human studies. Therefore, it is of clinical interest to develop experimental platforms to test repetitive PLIFUS as a therapeutic modality in humans with neurologic disorders. In the study described here, our aim was to develop a laboratory-built experimental device platform intended to deliver repetitive PLIFUS across the hippocampus in seizure onset zones of patients with drug-resistant temporal lobe epilepsy. The system uses neuronavigation targeting over multiple therapeutic sessions. PLIFUS (548 kHz) was emitted across multiple hippocampal targets in a human subject with temporal lobe epilepsy using a mechanically steered piezoelectric transducer. Stimulation was delivered up to 2.25 W/cm2 spatial peak temporal average intensity (free-field equivalent), with 36%–50% duty cycle, 500-ms sonications and 7-s inter-stimulation intervals lasting 140 s per target and repeated for multiple sessions. A first-in-human PLIFUS course of treatment was successfully delivered using the device platform with no adverse events. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
